Margriet Kwint

General introduction and outline of thesis 1 21 40. Borst GR, Sonke JJ, Betgen A, Remeijer P, van Herk M, Lebesque JV. Kilo-voltage cone- beam computed tomography setup measurements for lung cancer patients; first clinical results and comparison with electronic portal-imaging device. Int J Radiat Oncol Biol Phys. 2007;68(2):555-61. 41. Sonke JJ, Zijp L, Remeijer P, van Herk M. Respiratory correlated cone beam CT. Med Phys. 2005;32(4):1176-86. 42. Schaake EE, Rossi MM, Buikhuisen WA, Burgers JA, Smit AA, Belderbos JS, et al. Differential motion between mediastinal lymph nodes and primary tumor in radically irradiated lung cancer patients. Int J Radiat Oncol Biol Phys. 2014;90(4):959-66. 43. Brink C, Bernchou U, Bertelsen A, Hansen O, Schytte T, Bentzen SM. Locoregional control of non-small cell lung cancer in relation to automated early assessment of tumor regression on cone beam computed tomography. Int J Radiat Oncol Biol Phys. 2014;89(4):916-23. 44. Jabbour SK, Kim S, Haider SA, Xu X, Wu A, Surakanti S, et al. Reduction in Tumor Volume by Cone Beam Computed Tomography Predicts Overall Survival in Non-Small Cell Lung Cancer Treated With Chemoradiation Therapy. Int J Radiat Oncol Biol Phys. 2015;92(3):627-33. 45. Wald P, Mo X, Barney C, Gunderson D, Haglund AK, Bazan J, et al. Prognostic Value of Primary Tumor Volume Changes on kV-CBCT during Definitive Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer. J Thorac Oncol. 2017;12(12):1779-87. 46. Walraven I, Kwint M, Belderbos J. The Additional Prognostic Value of Tumor Volume Changes during Chemoradiotherapy in Patients with Stage III Non-Small Cell Lung Cancer. J Thorac Oncol. 2018;13(9):e181-e2. 47. Proust-Lima C, Sene M, Taylor JM, Jacqmin-Gadda H. Joint latent class models for longitudinal and time-to-event data: a review. Stat Methods Med Res. 2014;23(1):74-90. 48. Proust-Lima C, Taylor JM. Development and validation of a dynamic prognostic tool for prostate cancer recurrence using repeated measures of posttreatment PSA: a joint modeling approach. Biostatistics. 2009;10(3):535-49. 49. Twisk J, Hoekstra T. Classifying developmental trajectories over time should be done with great caution: a comparison between methods. J Clin Epidemiol. 2012;65(10):1078-87. 50. Walraven I, Mast MR, Hoekstra T, Jansen AP, van der Heijden AA, Rauh SP, et al. Distinct HbA1c trajectories in a type 2 diabetes cohort. Acta Diabetol. 2015;52(2):267-75. 51. Palma DA, Senan S, Oberije C, Belderbos J, de Dios NR, Bradley JD, et al. Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: an individual patient data meta-analysis. Int J Radiat Oncol Biol Phys. 2013;87(4):690-6. 52. Dankers F, Wijsman R, Troost EGC, Tissing-Tan CJA, Kwint MH, Belderbos J, et al. External validation of an NTCP model for acute esophageal toxicity in locally advanced NSCLC patients treated with intensity-modulated (chemo-)radiotherapy. Radiother Oncol. 2018;129(2):249-56. 53. Dehing-Oberije C, De Ruysscher D, Petit S, Van Meerbeeck J, Vandecasteele K, De Neve W, et al. Development, external validation and clinical usefulness of a practical prediction model for radiation-induced dysphagia in lung cancer patients. Radiother Oncol. 2010;97(3):455-61.